Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio

ALS Data For Verdiperstat Expected In 2022

The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.

A Businessperson Stopping Colorful Dominoes From Falling On Desk
Late-stage failures have stopped Biohaven from achieving success outside of its migraine pipeline • Source: Alamy

Biohaven Pharmaceutical Holding Company Ltd. wants to be a player in neurological and neuropsychiatric diseases, but the company has yet to report a clinical trial success outside of its CGRP inhibitor platform for the treatment of migraine. The most recent setback, disclosed on 27 September, is the failure of the myeloperoxidase (MPO) enzyme inhibitor verdiperstat in multiple system atrophy (MSA) to differentiate from placebo on the primary and secondary endpoints in a Phase III trial.

Analysts consistently viewed the setback as a minor event for Biohaven since the company’s valuation is largely based on the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D